Contact Us
  • or call us @ 801.538.8622
  • This field is for validation purposes and should be left unchanged.

USTAR Funded Projects

SAB Capra

SAB Capra Partnered with USU* for this project.

This project focuses on targeted human immunoglobulin to treat infectious diseases and aims to find less expensive antibody production and potential to increase consistency in batches of therapeutics.

SAB Capra, LLC. is a privately-held, emerging bioscience company developing targeted human polyclonal antibodies for use in diagnostics and testing, immunotherapeutics and personalized medicine applications. The company is advancing its novel antibody production platform leveraging transgenic goats utilizing some of the most advanced polyclonal science in the world.

The company is a Utah-based wholly owned subsidiary of SAB Biotherapeutics, Inc. a clinical-stage biopharmaceutical company developing human antibody therapeutics using its first-of-its-kind natural human immunotherapy platform leveraging transgenic animals genetically designed to produce large amounts of human polyclonal antibodies in response to a target disease.

*grant funds are awarded to the university partner and matched by the industry partner.

Learn more at sabcapra.com

Irina Polejaeva

Irina Polejaeva is using advanced gene transfer technology to understand heart arrhythmia that puts humans at risk for heart attacks and strokes.

View university profile here

Young-Min Lee

Young-Min Lee has applied molecular cloning techniques in developing a potential Zika vaccine. This process is safer and more efficient than traditional methods.

View university profile here

Timothy Doyle

Timothy Doyle is developing a high frequency ultrasound emitter to help detect cancer. The technology may be used to pinpoint the margins of tumors more precisely than any other method currently in use.

Teruo Okano

Teru Okano’s research team is creating new cell sheets that will allow for creating “patches” for damaged organs such as heart, artiledge and other human organs.

View university profile here

Steven Castle

Steven Castle has discovered a new effect of specialized amino acids to protect peptides against degradation. These can be used to improve the therapeutic window of the medicine.

View university profile here

Shawn Owen

Shawn Owen has invented a customizable, quick, single-step diagnostic assay to detect proteins through their properties as antigens or antibodies.

View university profile here

Jon Takemoto

Jon Takemoto is developing a chemical that will reduce the overuse of chemical fungicides to control crop and turf diseases. Compound mixtures are being assessed for their economic and environmental impact.

View university profile here

Jixun Zhan

Jixun Zhan has developed a synthetic biomanufacturing process to produce a blue dye with natural antioxidant and anti-microbial effects. Applications include textiles, food, beverages, and cosmetics.

View university profile here

Danny Chou

Danny Chou has identified a lead molecule for an ultra-fast acting human insulin. Such insulins are important for meal-time use by persons with Type l diabetes.

View university profile here

Craig Selzman

Craig Selzman is exploring a treatment for severe heart failure through a combination of electrical stimulation of nerves and a mix of tissue repair proteins and stem cells to improve heart function.

View university profile here

Sharpeyes

Sharp Eyes is developing adaptive lenses with software that continuously adjusts the lens magnification to give clear images at very near and midrange distances, eliminating bifocals.

Read about Sharpeyes

Navigen Pharmaceuticals

Navigen Pharmacetuals is a drug discovery and development company that is currently focusing on treatment and prevention of HIV and respiratory syncytial virus (RSV) as well as promising immune checkpoint targets for cancer therapies.

Learn more at navigenpharma.com

Base2 Genomics

Base2 Genomics provides a costeffective gene discovery analytic platform to discover the cause of rare and ultra-rare inherited conditions at a scale never before attempted.

Learn more at Base2 Genomics.com

KP Biosciences

KP Biosciences is a broad-spectrum antiviral company that is developing treatments for some of the world’s most problematic infectious diseases, including pox viruses and herpes viruses.

Learn more at kpbiosciences.com

Knudra Transgenics

Knudra Transgenics was formed in late 2009. The Knudra Team has a combined over 30 years of experience in making transgenic organisms. Knudra uses the latest advances in genome engineering to build powerful platforms of medical discovery. Knudra uses technology licensed from the University of Utah to turn a small-model organisms into a platform for biomedical discovery.

Learn more at knudra.com

T3S Technologies

T3S Technologies is advancing protein bio-manufacturing through proprietary bacterial hosts. This will significantly increase the effective yield of product and reduce cost.

Learn more at t3sbio.com

Contact Us
  • or call us @ 801.538.8622
  • This field is for validation purposes and should be left unchanged.